Among 1,396 patients with systemic lupus erythematosus (SLE) followed across 8,708 person-years, statin use failed to demonstrate protective effects against primary cardiovascular events (CVEs) — including myocardial infarction, thrombotic stroke, angina onset, and coronary bypass. CVE rates per 1,000 person-years were actually higher in statin users (8.5 for sub-standard dosing, 8.0 for standard dosing) versus non-users (5.3), with no statistical significance (p=0.31). Multivariable analysis returned an odds ratio of 1.48 (95% CI 0.79–2.75) for statin use — directionally unfavorable, though non-significant. Diabetes mellitus emerged as the strongest independent predictor (OR 4.48), followed by prednisone ≥10 mg/day and BMI 25–30 kg/m².
This finding challenges a foundational assumption in SLE cardiology: that statins, proven effective in general population primary prevention, translate equivalently to autoimmune populations. SLE-specific cardiovascular drivers — chronic inflammation, immune dysregulation, and corticosteroid burden — may overwhelm the lipid-lowering benefits statins provide. The JUPITER and SATURN trials excluded high-inflammation autoimmune cohorts, leaving this gap largely unaddressed. Importantly, confounding by indication almost certainly inflates CVE rates among statin users here, since clinicians prescribe statins to higher-risk patients — a limitation the authors acknowledge through multivariable adjustment, though residual confounding remains plausible. The cohort is 92% female and racially diverse, strengthening generalizability to the typical SLE population. As a preprint posted to medRxiv and not yet peer-reviewed, these conclusions require independent validation before influencing clinical guidelines. Still, this is a clinically significant signal warranting prospective trials of statin efficacy specifically in SLE.
